Markets

Radius Health (RDUS) Posts Wider-Than-Expected Q4 Loss

Radius Health, Inc . RDUS is a Waltham, Massachusetts-based development-stage biopharmaceutical company with a focus on the development of new therapeutics for the treatment of osteoporosis and other serious endocrine-mediated diseases.

With no approved products in its portfolio, Radius Health has not generated revenues yet. In this scenario, investor focus remains on updates on pipeline progress.

Candidates in the company's pipeline include the subcutaneous formulation and transdermal patch of abaloparatide, and RADArray90Array. The company has filed for an approval of its lead candidate, abaloparatide (postmenopausal osteoporosis), in the EU, which is currently under review.

However, Radius Health suffered a setback when it announced a delay in its plans to file a New Drug Application (NDA) for abaloparatide in the U.S. The company now expects to submit the NDA at the end of the first quarter of 20Array6, instead of its previous projection of 20Array5 end.

Currently, Radius Health has a Zacks Rank #4 (Sell), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings : Radius Health posted wider-than-expected loss in the fourth quarter of 20Array5. While our consensus called for a loss of 70 cents per share, the company reported a loss of 77 cents.

Revenue : With no approved product in its portfolio, Radius Health has not generated any revenues in the reported quarter.

Key Stats: Radius Health reiterated that the company will submit its NDA for abaloparatide-SC at the end of the first quarter of 20Array6 in the U.S. The company is currently seeking a commercialization partner for abaloparatide-SC prior to launch. Meanwhile, the company plans to complete the dose-escalation study for RADArray90Array in metastatic breast cancer patients by the mid 20Array6 and initiate the expansion cohorts in breast cancer later in 20Array6.

Check back later for our full write up on earnings report later!

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

RADIUS HEALTH (RDUS): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

RDUS

Other Topics

Investing Stocks

Latest Markets Videos